Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Cancers · 24.01.2023 · 15 (3) · 713
DOI: 10.3390/cancers15030713 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.01.2023. Verfasst von Toan D Nguyen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA. Die Arbeit wurde bisher 445-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, University at Buffalo Center for Protein Therapeutics.
Abstract (Originalsprache)
Anti-cancer antibody-drug conjugates (ADCs) aim to expand the therapeutic index of traditional chemotherapy by employing the targeting specificity of monoclonal antibodies (mAbs) to increase the efficiency of the delivery of potent cytotoxic agents to malignant cells. In the past three years, the number of ADCs approved by the Food and Drug Administration (FDA) has tripled. Although several ADCs have demonstrated sufficient efficacy and safety to warrant FDA approval, the clinical use of all ADCs leads to substantial toxicity in treated patients, and many ADCs have failed during clinical development due to their unacceptable toxicity profiles. Analysis of the clinical data has demonstrated that dose-limiting toxicities (DLTs) are often shared by different ADCs that deliver the same cytotoxic payload, independent of the antigen that is targeted and/or the type of cancer that is treated. DLTs are commonly associated with cells and tissues that do not express the targeted antigen (i.e., off-target toxicity), and often limit ADC dosage to levels below those required for optimal anti-cancer effects. In this manuscript, we review the fundamental mechanisms contributing to ADC toxicity, we summarize common ADC treatment-related adverse events, and we discuss several approaches to mitigating ADC toxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
ORCID-Profile: Joseph P Balthasar
Förderung
- NCI NIH HHS
- National Cancer Institute
- University at Buffalo Center for Protein Therapeutics
Zitieren
APA
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023). Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 15(3), 713. https://doi.org/10.3390/cancers15030713
Vancouver
Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers. 2023;15(3):713. doi:10.3390/cancers15030713
BibTeX
@article{Nguyen2023,
author = {Nguyen, Toan D and Bordeau, Brandon M and Balthasar, Joseph P},
title = {Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability},
journal = {Cancers},
year = {2023},
volume = {15},
number = {3},
pages = {713},
doi = {10.3390/cancers15030713}
}
EUVIMED